tion of PGE2 receptors in fetal and newborn lamb ductus arteriosus. Am J Physiol Heart Circ Physiol 280: H2342-H2349, 2001.-Although the role of PGE2 in maintaining ductus arteriosus (DA) patency is well established, the specific PGE2 receptor subtype(s) (EP) involved have not been clearly identified. We used late gestation fetal and neonatal lambs to study developmental regulation of EP receptors. In the fetal DA, radioligand binding and RT-PCR assays virtually failed to detect EP1 but detected EP2, EP3D, and EP4 receptors in equivalent proportions. In the newborn lamb, DA total density was one-third of that found in the fetus and only EP 2 was detected. Stimulation of EP2 and EP4 increased cAMP formation and was associated with DA relaxation. Though stimulation of EP3 inhibited cAMP formation, it surprisingly relaxed the fetal DA both in vitro and in vivo. This EP3-induced relaxation was specifically diminished by the ATP-sensitive K ϩ (KATP) channel blocker glibenclamide. In conclusion, PGE2 dilates the late gestation fetal DA through pathways that involve either cAMP (EP 2 and EP4) or KATP channels (EP3). The loss of EP3 and EP4 receptors in the newborn DA is consistent with its decreased responsiveness to PGE 2. ductus arteriosus; EP receptors; ATP-sensitive potassium channels.
THE DUCTUS ARTERIOSUS (DA) performs two major functions: to remain patent during fetal life and to close rapidly after birth to separate the pulmonary and systemic circulations (20) . Prostaglandins, particularly PGE 2 , play a major role in maintaining the patency of the fetal DA (12, 14, 15) . The relaxant effects of PGE 2 have been attributed to its ability to increase intracellular cAMP concentrations (17, 43) . Immediately after birth, the response of DA to PGE 2 is markedly reduced (2, 11) thereby promoting DA closure. The mechanisms for this decreased responsiveness to PGE 2 are not well understood.
PGE 2 exerts its effects through a diverse group of receptors classified as EP 1 , EP 2 , EP 3 , and EP 4 (16) . Although pharmacological evidence suggests that EP 4 may be the main functional PGE 2 receptor in fetal rabbit DA (40) , genetic disruption of this receptor does not induce DA closure in either fetal or newborn mice (34) . Thus at present, the types of PGE 2 receptors that govern DA tone are uncertain. We (5) have recently found that the DA of the fetal pig expresses three EP receptor subtypes that would appear to have different effects on ductus contractile tone. We identified two cAMP-stimulating EP receptors (EP 2 and EP 4 ) and one cAMP inhibiting receptor (EP 3 ). In contrast, we detected only EP 2 in the newborn pig (5) . However, it remains to be explained how loss of a cAMP-inhibiting (EP 3 ) and a cAMP-stimulating (EP 4 ) EP receptor can result in decreased responsiveness of the newborn DA to PGE 2 .
Therefore we proceeded to determine the developmental profile of EP receptor expression in another species, the ovine, and to examine the effects of EP receptor stimulation on DA signaling events and contractile responses. Our findings reveal that the fetal lamb expresses, in equal proportions, the same three EP receptor subtypes detected in the fetal pig (5) . Similarly, EP 2 is the only EP receptor identified by binding studies in the newborn ovine DA. Although stimulation of cAMP-generating EP 2 and EP 4 receptors resulted in the expected DA relaxation, surprisingly stimulation of cAMP-inhibiting EP 3 receptors also produced relaxation. This effect was mediated via a previously undescribed cAMP-independent pathway for EP 3 involving activation of ATP-sensitive K ϩ (K ATP ) channels. The loss of a relaxant EP 3 receptor in the newborn DA is consistent with decreased responsiveness of the DA to PGE 2 in the immediate neonatal period. ; Valium, Hoffman-Laroche) and fetal lambs (mixed Western breed) delivered by cesarean section at 135 Ϯ 3 days gestation (range, 125-140 days; term, 145 days). The fetus was given ketamine (30 mg/kg iv) before exsanguination to obtain DA. The same procedure was used to obtain DA from the newborn (Ͻ8 h after birth). Vessels were frozen immediately after removal with liquid N2 and stored at Ϫ80°C. These procedures were approved by the Committee on Animal Research at the University of California, San Francisco.
MATERIALS AND METHODS

Materials
Radioligand binding assays. [
3 H]PGE2 binding and displacement studies were performed as described previously on DA membranes (5, 25) . Frozen ductuses (with endothelium) were homogenized with a tissue grinder in 10 mM PBS buffer (pH 7.4) containing soybean trypsin inhibitor (1 mg/ml) and phenylmethylsulfonyl fluoride (PMSF, 5%). The homogenate was then centrifuged twice at 10,000 g for 15 min at 4°C to remove nuclei, undisrupted cells, and fibrous tissue. The combined supernatants were recentrifuged at 100,000 g for 90 min at 4°C. The membrane pellet was stored at Ϫ80°C (necessary to pool tissues) and used for receptor binding assay within 1 wk.
Aliquots of DA membranes (100-200 g protein) were incubated at 37°C for 30 min in 100 l of 10 mM PBS buffer (pH 7.4) containing soybean trypsin inhibitor (1 mg/ml) and PMSF, 5%. [ 3 H]PGE2 was added in the absence or presence of increasing doses of a nonselective EP agonist (16,16-dimethyl-PGE 2), an EP1 antagonist (AH-6809), an EP2 agonist (butaprost), an EP 3 agonist (M&B-28767), and an EP4 antagonist (AH-23848B). Total EP receptor density (Bmax) was determined using the equation Bmax ϭ B0 ϫ (IC50/L), where B0 is the specific binding of [ 3 H]PGE2 at 0% displacement and L the concentration of free-labeled ligand (18) , with the use of the computer program PRISM (GraphPad) which also calculated IC50 values. Because the affinity of PGE2 for EP receptors (especially EP2, EP3, and EP4) is comparable (1) one could determine their proportions (18, 28) .
cAMP measurements. DA homogenates (100 g protein) were incubated at 37°C for 10 min in an assay mixture (100 L) containing: 10 mM Tris ⅐ HCl buffer (pH 8.0), 1 mM ATP, 7.5 mM MgCl2, 15 mM creatine phosphate, 0.5 mM EGTA, 0.5 mM IBMX, 1 mM dithiothreitol, 1 mM benzamidine, 0.1 mM PMSF, and 185 U/ml creatine phosphokinase, 200 g/ml aspirin, and 100 g/ml soybean trypsin inhibitor (5, 25) . The reaction was terminated with 200 l of acidic ethanol. After centrifugation, cAMP was measured by radioimmunoassay as described by the manufacturer (Diagnostic Products). The assay is based on the competition between unlabeled cAMP and a fixed quantity of tritium-labeled compound ([ 3 H]cAMP) for binding to an antiserum which has a high specificity for cAMP. The amount of [ 3 H]cAMP bound to the antiserum is inversely related to the amount of cAMP present in the assay sample. Separation of the unbound nucleotide (including radiolabeled) is achieved by dextran-coated charcoal adsorption. The radioactivity of the supernatant (which contains the antibody-[ 3 H]cAMP complex) is determined by liquid ␤-scintillation counting. The concentration of unlabeled cAMP in the sample is then determined from a standard curve.
Isometric tension in vitro. The freshly collected DA was divided into 1-mm thick rings placed in separate 10-ml organ baths in a darkroom as previously described (12, 13). The rings were suspended between two stainless steel hooks at 38°C in a modified Krebs buffer (pH 7.4) of the following composition (in mM): 118 NaCl, 4.7 KCl, 2.5 CaCl 2, 0.9 MgSO4, 1 KH2PO4, 11.1 glucose, and 23 NaHCO3 (pH 7.4). The buffer was equilibrated with 5% CO 2-30% O2-65% N2. In some rings the luminal endothelium was removed by scraping the surface with a fine wire as previously described (13) . The bath solution was changed every 20 min. Isometric tension was measured by Grass FTO3C force transducers (Quincy, MA). The tissues were equilibrated with 30% O 2, 65% N2, and 5% CO2 until the tension reached a plateau (ϳ100-120 min). Indomethacin at 5.6 M [a dose that was previously reported to cause maximal inhibition of PGE 2 or 6-keto-PGF1␣ production in the ductus (10,13)] was then added to the bath solution, and the rings were allowed to reach a new steady-state tension over the next 60-90 min. The nitric oxide (NO) synthase inhibitor, N G -nitro-L-arginine methyl ester (L-NAME) (0.1 mM) was then added to a dose previously found to cause the maximal inhibition of NO synthesis in the ductus (10, 13) . The rings were exposed to indomethacin and L-NAME for the remainder of the study protocol. Maximal contraction was determined from the response to a 100 mM KCl that gave the maximal contraction of the ductus (13) .
Sensitivity of the DA to relaxing agents was determined from vessels precontracted with indomethacin and L-NAME (precontraction tension). Cumulative dose-response curves were constructed for PGE2, butaprost, M&B-28767, and GR-63799X (also an EP 3 agonist), cicaprost and carbaprostacyclin (PGI2 analogs), as well as cAMP stimulants and mimetics [forskolin and 8-bromoadenosine 3Ј,5Ј-cyclic monophosphate (8-Br-cAMP)]. The concentrations that produce 50% of maximal response (EC50 values) were determined from each dose-response curve. In some experiments, a cumulative dose-response curve was performed to a relaxing agent after the tissue had been equilibrated with either an EP4 receptor antagonist (AH-23848B) or one of the following K ϩ channel inhibitors 4-aminopyridine (4AP), iberiotoxin, or glibenclamide (33) . In all experiments, we allowed the tension in the rings to reach a new steady-state plateau after addition of the drug and before another concentration or experimental agent was added to the bath. After the addition of all prorelaxant drugs, sodium nitroprusside (0.1 mM) was added to each ring to determine its minimal tension. The difference between the maximal contraction and minimal tension was considered the maximal active tension (20 Ϯ 3 g, n ϭ 120). The difference in tensions between the precontraction tension (with indomethacin and L-NAME) and the minimal tension (with sodium nitroprusside) was considered the net tension (15 Ϯ 3 g, n ϭ 120). The tension was expressed as a percentage of the net tension. Tissues were removed from the baths after the experiments and wet weights recorded.
Effects of different agents on DA tone in vivo. Pregnant ewes (120-140 days of gestation) were anesthetized with ketamine (30 mg/kg iv). A cesarean section was performed and the fetus with intact placental circulation was exteriorized and its head submerged in warm saline to prevent breathing. Body temperature was maintained at 38.5°C by an overhead lamp. The femoral artery was cannulated for blood pressure recording using a pressure transducer (Gould, Valley View, OH), and the jugular vein was cannulated for the administration of drugs. Arterial blood gas was measured with an ABL300 blood gas analyzer (Radiometer, Copenhagen, Denmark) before and after each drug infusion.
Ultrasonography of DA. Real-time and Doppler echographic studies were performed with an Acuson 128 XP/10c real-time ultrasonographic imaging system that used 7.5-and 5-MHz transducers as previously described (6) . Twodimensional imaging of the DA was obtained through a left parasternal approach (second intercostal space), and the angulation of the transducer was such that the ultrasonographic beam was always parallel to or within 20 degrees of the orientation of the blood flow. The DA was preconstricted with indomethacin (0.75 mg/kg) to Ͻ50% of the original diameter. Vasorelaxant responses to sulprostone (EP 3 agonist) were determined by measuring the smallest diameter of the vessel on a two-dimensional representation of the echocardiogram before and every 5-10 min after the drug injections. Each measurement of the DA diameter was repeated twice and expressed in mm.
Preparation of total RNA, reverse transcription, and polymerase chain reaction. Total RNA was isolated from fetal DA tissue using the QIAGEN RNeasy mini kit (QIAGEN; Valencia, CA) according to manufacturer instructions. Total RNA (3 g) was reverse transcribed with 100 units of Moloney murine leukemia virus Rnase H reverse transcriptase (Life Technologies) in the presence of random hexanucleotide primers as described elsewhere (34, 45) . The cDNAs were used for the amplification of specific fragments of EP 2, EP3, and EP4 receptors by PCR following standard procedures (35 amplification cycles) (34, 45) . To amplify a fragment composed of the transmembrane domain I and the second intracellular loop of the EP2 receptor, the forward primer 5Ј-ATCTTGGGGTGGTGGGCAA-3Ј and the reverse primer 5Ј-CGCTTGTCCACGTAGTGGCT-3Ј were used. To amplify an EP3 receptor fragment composed of the transmembrane domains IV and V, the forward 5Ј-GTGCTCGCCTTCGCCCT-GTT-3 and reverse 5Ј-GCCTTGGCCCTGCAGCGGGA-3Ј primers were used. To amplify COOH-termini of the EP3A,B,C isoforms the forward primer 5Ј-ATAATGATGTTG-AAAATGAT-3Ј was used with the reverse primers R3 5Ј-CTACTGATGCTCAAGTGTATG-3Ј and R4 5Ј-GCCCC-CTTCCTCTCCTTGCTT-3Ј. Primer R5 5Ј-ATTTCATTG-GATAGTGAGATAGTC-3Ј was used to amplify the EP 3D COOH-terminal. The forward and reverse primers used to amplify the EP 4 receptor were 5Ј-AAGTCGCGCAAG-GAGCAGAA-3Ј and 5Ј-CTTGTCCACGTAGTGGCTGT-3Ј, respectively. The PCR products were subcloned into the pPCR-Script Amp SK(ϩ) plasmid (Stratagene, La Jolla, CA) and sequenced with the use of an ABI prism 310 Genetic Analyzer sequencer (PE Applied Biosystems, Foster City, CA).
Statistical analysis. Data were analyzed by Student's ttest and by two-way ANOVA factoring for time or concentration and treatment. The Bonferroni correction was used for comparison among means. Statistical significance was set at P Ͻ 0.05. Data are expressed as means Ϯ SE. (Fig. 1B) . The EP 1 receptor antagonist AH-6809 was virtually ineffective (Fig. 1, A and B values were consistent with those previously reported in the literature (1, 16, 32) .
RESULTS
Competitive displacement of
Effects of different agents on cAMP production in the fetal DA. Both the nonselective EP receptor agonist 16,16-dimethyl-PGE 2 and the selective EP receptor agonist butaprost increased cAMP production in the fetal lamb DA (Table 2 ). In contrast, the selective EP 3 receptor agonist GR-63799X had no effect on cAMP production by itself but inhibited forskolin-stimulated cAMP production ( Table 2 ). In the absence of currently available EP 4 agonists, the role of EP 4 was tested with the use of the EP 4 antagonist AH-23848B in the presence of 16,16-DM PGE 2 . AH-23848B alone did not alter cAMP production but decreased 16,16-DM PGE 2 -induced stimulation of cAMP formation (Table 2) , which suggests that stimulation of EP 4 receptors accounts for some of the increased cAMP production induced by the nonselective EP receptor agonist.
Effects of different agents on fetal DA tension in vitro. The fetal DA contracted spontaneously (77 Ϯ 8% maximal active tension) after addition of indomethacin and L-NAME (in the presence of 30% oxygen). As anticipated, agents that led to elevations in cAMP levels, namely forskolin and 8-Br-cAMP, relaxed the fetal DA (Fig. 2, A and B) with relatively low potency as previously described (37, 41) . Analogs of PGI 2 , the effects of which are also coupled to an increase in cAMP (16) , relaxed the DA albeit with a potency Ͻ1,000 time less than PGE 2 (Fig. 2C, Table 3 ). Similarly, stimulation of EP receptors that increase cAMP relaxed the DA; the nonselective EP agonist PGE 2 and the selective EP 2 agonist butaprost relaxed the DA (Fig. 2, C and D) , and inhibition of the EP 4 receptor with AH-23848B inhibited the relaxant effects of PGE 2 (Fig. 2E, Table 3 ). In contrast, although EP 3 stimulation decreased cAMP production (Table 3) , activation of EP 3 receptors with M&B-28767 or GR-63799X caused relaxation of the (preconstricted) fetal DA by Ͼ70% (Fig. 2F) . To assess whether effects of EP 3 were G protein-dependent, tissues were treated with pertussis toxin, which diminished the inhibitory effect of M&B-28767 on cAMP formation but did not alter its relaxant actions.
Effects of PGE 2 analogs on the diameter of the fetal DA in vivo.
We also tested the effects of EP 3 stimulation on DA tone in vivo. Infusion of the EP 3 receptor agonist sulprostone relaxed the indomethacin-induced contraction of the fetal DA in vivo (Fig. 3 ) consistent with our in vitro results (Fig. 2F) ; a similar effect was seen with 16,16-dimethyl-PGE 2 (data not shown).
Role of K ϩ channels on EP receptor-induced fetal DA relaxation. Because EP 3 receptor stimulation caused DA relaxation, despite reducing cAMP generation, we examined whether EP receptor stimulation might relax the DA through other signaling pathways. K ϩ channels have previously been shown to play a role in DA tone (30, 42) . We performed PGE 2 dose-response curves in the presence and absence of specific K ϩ channel inhibitors. The relaxant effects of PGE 2 were not affected by the voltage-gated potassium-and calcium-activated potassium-channel blockers 4-aminopyridine and iberiotoxin, respectively (Table 3 ). However, the K ATP channel blocker glibenclamide significantly inhibited the relaxation caused by the EP 3 agonist M&B-28767. Glibenclamide did not affect relaxation caused by agents that increase cAMP (butaprost, forskolin, and 8-Br-cAMP) ( Table 3) . Removal of luminal endothelial cells neither altered the PGE 2 -or M&B-28767-induced relaxation of the DA nor did it modify the inhibitory effects of glibenclamide on PGE 2 and M&B-28767-induced relaxation (Table 4) .
Detection of EP receptor subtypes and isoforms in the fetal DA by PCR. We amplified an EP 3 receptor fragment from the ovine DA that encompassed transmembrane domains IV and V of the receptor. Because its sequence was 100% homologous with the corresponding bovine sequence (31), we designed oligonucleotide primers on the basis of the bovine sequence to identify which of the different EP 3 receptor carboxyterminal isoforms might be present in the fetal DA (31) . Only the EP 3D isoform fragment was successfully amplified from the ovine fetal DA. The PCR product sequence identified was 100% homologous with that of the bovine EP 3D (for relevant bases 895-1145 from the cDNA sequence) (31). Using EP 2 -specific primers, we amplified an EP 2 receptor fragment from the ovine fetal DA that had 90, 87, and 85% homology with the corresponding sequences from the human, mouse, and rat EP 2 receptors, respectively (4, 21, 35) . Using EP 4 specific primers, we also amplified an EP 4 fragment, which was virtually identical to the reported ovine EP 4 receptor sequence (GenBank accession AF035418) and had 94% homology with the corresponding sequence of the human EP 4 receptor (29) . The presence of EP 2 , EP 3D , and EP 4 receptor mRNAs in the fetal ovine DA is consistent with our displacement binding data ( Fig. 1 (Fig. 1, C and D, Table  1 ). EP 1 , EP 3 , and EP 4 receptors were essentially undetectable. The calculated B max for the EP 2 receptor in the newborn was the same as that calculated for the EP 2 receptor in the fetus (Fig. 1, B and D) .
DISCUSSION
Results presented help to identify the types of PGE 2 receptors that govern DA tone and how developmental changes in their expression may explain the decreased responsiveness of the DA to PGE 2 in the immediate newborn period. We have previously reported the presence of EP 2 , EP 3 , and EP 4 receptors in the porcine fetal DA, and the loss of EP 3 and EP 4 in the newborn (5) . Stimulation of EP 3 and EP 4 led to opposite effects on DA rings were precontracted with 30% oxygen, indomethacin (5.6 M), and N G -nitro-L-arginine methyl ester L-NAME (0.1 mM). Difference in tension between the one induced by indomethacin ϩ L-NAME and that generated after sodium nitroprusside (0.1 mM) was considered the net tension (15 Ϯ 3 g, n ϭ 120). Dose responses to forskolin, 8-bromoadenosine 3Ј,5Ј-cyclic monophosphate (8-Br-cAMP) PGE2, PGI2 analogs cicaprost and carbaprotacyclin, butaprost, M&B-28767, and GR-63799X were studied; effects of PGE2 were also tested in the presence of EP4 antagonist AH-23848B. Tension is expressed as a percentage of the net tension. Values are means Ϯ SE of 3-11 experiments. cAMP formation (5) . Decreases and increases in cAMP are usually associated with constriction and relaxation, respectively. Therefore, it was difficult to reconcile how the loss of receptors with apparently opposing actions could account for the changes in vasomotor tone that occurred in the DA immediately after birth (2, 11) . The present study in the ovine DA demonstrates that these perinatal changes in EP receptor profile are not just limited to the pig. More importantly, the findings unveil a previously unreported vasomotor response to EP 3 stimulation, namely, a robust relaxation mediated by activation of K ATP channels and not by increases in cAMP. The loss of two EP receptors coupled to relaxation (EP 3 and EP 4 ) in the early postnatal DA provides an explanation for its decreased responsiveness to PGE 2 .
Stimulation of EP 2 and EP 4 receptors in the fetal lamb increased cAMP and relaxed the DA as expected (16) . Despite reducing cAMP production, stimulation of EP 3 receptors also relaxed the DA (to an extent that was even greater than stimulation of EP 2 ). This EP 3 -induced relaxation was shown in vitro as well as in vivo with the use of distinct selective EP 3 stimulants (M&B-28767, GR-63799X, and sulprostone) (1, 16) . The relaxant effect of EP 3 agonists on the fetal DA was due, at least in part, to stimulation of a glibenclamide-sensitive K ATP channel, whereas that of cAMP-elevating agents was not (Table 3 ). This failure of glibenclamide to inhibit relaxation by cAMP-elevating agents is not unique to the DA; relaxation of many (but not all) blood vessels to cAMP-elevating agents has been reported to be unaffected by glibenclamide (22, 23, 36) . Altogether, relaxation of the DA to PGE 2 seems to be at least partly dependent on cAMP (EP 2 and EP 4 ) and K ATP (EP 3 ) pathways.
The mechanisms responsible for the EP 3 -induced, K ATP -dependent relaxation of the DA are unclear. PGE 2 has been reported to be coupled to K ATP or calcium-activated potassium channels in different tissues (3, 7) ; NO-mediated, cGMP-dependent kinase- (8, 19) and protein kinase A-mediated processes have been proposed (43) . In our studies a role for protein kinase A appears to be unlikely because cAMP elevating agents (butaprost, forskolin, 8-Br-cAMP) did not relax the DA in a glibenclamide-sensitive manner. Similarly, a role for NO or endothelial derived prostanoids also appears to be unlikely because the relaxant responses of the EP 3 agonists were observed in DA tissues pretreated with NO synthase and cyclooxygenase inhibitors. Furthermore, removal of luminal endothelium did not modify either the EP 3 -induced relaxation or its dependence on the K ATP channel. The EP 3 receptor has numerous isoforms that couple to different G proteins (24, 31) . These have the potential to elicit different vasoactive responses. We identified an EP 3 isoform in the ovine DA identical to the bovine EP 3D receptor (31) that can couple to G i , G s , and G q (31) . It is unlikely that the EP 3D receptor stimulates the K ATP channel through a G s -stimulated process: EP 3 stimulation inhibited rather than stimulated cAMP in the DA and cAMP did not relax the DA in a glibenclamide-sensitive manner (Tables 2, 3 ). In most tissues, the EP 3 receptor couples with G i (16, 24, 31, 32) , which is responsible for the inhibition of cAMP production; however, pertussis toxin, an inhibitor of G i , blocked the effects of EP 3 stimulation on cAMP inhibition but did not affect the EP 3 -induced relaxation. Hence, G i may also not be involved in the EP 3 -induced DA relaxation. Coupling of the receptors to G q could lead to relaxation if they were present on the endothelium (9, 27, 39) ; however, this is not consistent with our findings because EP 3 -induced relaxation was not inhibited by removal of the luminal endothelium. Possible explanations for this novel function of EP 3 include activation of K ATP by NO-independent protein kinase G in response to EP 3 stimulation (44) or heterodimerization of EP 3 with the K ATP chan- Fig. 3 . Effects of EP3 agonist sulprostone on percent change in DA diameter of fetal lambs in vivo. Animal preparation is described in MATERIALS AND METHODS. Briefly, the fetal lamb with intact placental circulation was exteriorized and its head submerged in warm saline to prevent breathing. The femoral artery and jugular vein were cannulated. DA diameter was measured by echocardiogram. DA was preconstricted with indomethacin (0.75 mg/kg iv) and once its diameter was Ͻ50% of the original diameter, sulprostone (0.083 g ⅐ kg Ϫ1 ⅐ min Ϫ1 iv) was infused (indicated by shaded area along the abscissa). Values are means Ϯ SE of 3 experiments. *P Ͻ 0.05 compared with presulprostone infusion. nel as described with other G protein-coupled receptors (26) . Extensive studies are in progress to address these issues.
Perspectives. In summary, total EP receptors in the lamb DA decrease after birth. The loss of both a vasodilating EP 4 receptor and a previously undescribed vasodilating EP 3 receptor could explain the loss of vasodilatory response of the DA to PGE 2 in the early newborn period. Present data in the ovine DA support those in the porcine DA (5). They also suggest that a selective EP 2 agonist may be more appropriate than the nonselective agonist PGE 1 for maintaining ductal patency in newborn infants afflicted with certain congenital cardiac malformations.
